US Biopharmaceutical Company Liminatus Pharma Plans to Raise $500 Million to Invest in BNB
BlockBeats News, July 28th, According to a report by businessinsider, Clinical-stage biopharmaceutical company Liminatus Pharma, Inc. (NASDAQ: LIMN) today announced plans to strategically expand into the cryptocurrency and blockchain space.
The company plans to establish a subsidiary named "American BNB Strategy" to lead its digital asset investment and management plan. Through this platform, Liminatus plans to gradually raise and deploy up to $500 million in funds, with the goal of strategically long-term investing in BNB.
Liminatus emphasized that while the company remains fully committed to its core business - advancing cancer treatments and pancreatic cancer diagnostic technologies, expanding into the digital asset space is seen as a necessary step to support long-term growth and enhance shareholder value.
Liminatus is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer patients. The company is advancing a series of novel therapies targeting cancer antigens and tumor-specific immune responses.
You may also like
Gainers
Latest Crypto News
Cysic Foundation: Airdrop Eligibility Check Tool Now Live
WSJ: Investors are Wary of a New Round of the "Crypto Winter"
Aethir Releases 12-Month Future Roadmap to Accelerate Growth in Global Enterprise AI Computing Business
24-hour Spot Funding Inflow/Outflow List: ETH Net Outflow of $126 million, ZEC Net Outflow of $18.2 million
Bloomberg: Fed Never So Split on Long Rate Strategy
Customer Support:@weikecs
Business Cooperation:@weikecs
Quant Trading & MM:bd@weex.com
VIP Services:support@weex.com